These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Chronic kidney disease and cardiovascular disease--using the ANNA Standards and Practice Guidelines to improve care. Part 1: the epidemiology of chronic kidney disease: the risk factors and complications that contribute to cardiovascular disease. McCarley PB; Burrows-Hudson S Nephrol Nurs J; 2006; 33(6):666-74; quiz 675-6. PubMed ID: 17219728 [TBL] [Abstract][Full Text] [Related]
25. Minor abnormalities of renal function: a situation requiring integrated management of cardiovascular risk. Segura J; Ruilope LM Fundam Clin Pharmacol; 2005 Aug; 19(4):429-37. PubMed ID: 16011729 [TBL] [Abstract][Full Text] [Related]
26. Endothelial dysfunction in cardiovascular disease: risk factor, risk marker, or surrogate end point? Elliott HL J Cardiovasc Pharmacol; 1998; 32 Suppl 3():S74-7. PubMed ID: 9883752 [TBL] [Abstract][Full Text] [Related]
28. Cross-talk between the kidney and the cardiovascular system. Amann K; Wanner C; Ritz E J Am Soc Nephrol; 2006 Aug; 17(8):2112-9. PubMed ID: 16825329 [TBL] [Abstract][Full Text] [Related]
29. Evidence for the use of urinary albumin as marker of kidney involvement in unselected populations. McQueen MJ Scand J Clin Lab Invest Suppl; 2008; 241():52-6. PubMed ID: 18569965 [TBL] [Abstract][Full Text] [Related]
30. Endothelial dysfunction in obesity: etiological role in atherosclerosis. Meyers MR; Gokce N Curr Opin Endocrinol Diabetes Obes; 2007 Oct; 14(5):365-9. PubMed ID: 17940464 [TBL] [Abstract][Full Text] [Related]
31. Two cardiovascular risk factors in one? Homocysteine and its relation to glomerular filtration rate. A meta-analysis of 41 studies with 27,000 participants. Kielstein JT; Salpeter SR; Buckley NS; Cooke JP; Fliser D Kidney Blood Press Res; 2008; 31(4):259-67. PubMed ID: 18689992 [TBL] [Abstract][Full Text] [Related]
32. Endothelial dysfunction and the kidney: emerging risk factors for renal insufficiency and cardiovascular outcomes in essential hypertension. Zoccali C J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S61-3. PubMed ID: 16565249 [TBL] [Abstract][Full Text] [Related]
34. Should beta-blockers be used to control hypertension in people with chronic kidney disease? Hart PD; Bakris GL Semin Nephrol; 2007 Sep; 27(5):555-64. PubMed ID: 17868793 [TBL] [Abstract][Full Text] [Related]
35. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment]. Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737 [TBL] [Abstract][Full Text] [Related]